Literature DB >> 23808942

SERCA2 activity is involved in the CNP-mediated functional responses in failing rat myocardium.

L R Moltzau1, J M Aronsen, S Meier, C H T Nguyen, K Hougen, Ø Ørstavik, I Sjaastad, G Christensen, T Skomedal, J-B Osnes, F O Levy, E Qvigstad.   

Abstract

BACKGROUND AND PURPOSES: Myocardial C-type natriuretic peptide (CNP) levels are increased in heart failure. CNP can induce negative inotropic (NIR) and positive lusitropic responses (LR) in normal hearts, but its effects in failing hearts are not known. We studied the mechanism of CNP-induced NIR and LR in failing hearts and determined whether sarcoplasmatic reticulum Ca(2+) ATPase2 (SERCA2) activity is essential for these responses. EXPERIMENTAL APPROACH: Contractility, cGMP levels, Ca(2+) transient amplitudes and protein phosphorylation were measured in left ventricular muscle strips or ventricular cardiomyocytes from failing hearts of Wistar rats 6 weeks after myocardial infarction. KEY
RESULTS: CNP increased cGMP levels, evoked a NIR and LR in muscle strips, and caused phospholamban (PLB) Ser(16) and troponin I (TnI) Ser(23/24) phosphorylation in cardiomyocytes. Both the NIR and LR induced by CNP were reduced in the presence of a PKG blocker/cGMP analogue (Rp-8-Br-Pet-cGMPS) and the SERCA inhibitor thapsigargin. CNP increased the amplitude of the Ca(2+) transient and increased SERCA2 activity in cardiomyocytes. The CNP-elicited NIR and LR were not affected by the L-type Ca(2+) channel activator BAY-K8644, but were abolished in the presence of isoprenaline (induces maximal activation of cAMP pathway). This suggests that phosphorylation of PLB and TnI by CNP causes both a NIR and LR. The NIR to CNP in mouse heart was abolished 8 weeks after cardiomyocyte-specific inactivation of the SERCA2 gene. CONCLUSIONS AND IMPLICATIONS: We conclude that CNP-induced PLB and TnI phosphorylation by PKG in concert mediate both a predictable LR as well as the less expected NIR in failing hearts.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  C-type natriuretic peptide; heart failure; lusitropic response; negative inotropic response; sarcoplasmatic reticulum Ca2+ ATPase; troponin I

Mesh:

Substances:

Year:  2013        PMID: 23808942      PMCID: PMC3834760          DOI: 10.1111/bph.12282

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  Effects of natriuretic peptides on ventricular myocyte contraction and role of cyclic GMP signaling.

Authors:  Qihang Zhang; Jacob Moalem; James Tse; Peter M Scholz; Harvey R Weiss
Journal:  Eur J Pharmacol       Date:  2005-03-14       Impact factor: 4.432

2.  Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes.

Authors:  Jun Su; Peter M Scholz; Harvey R Weiss
Journal:  Exp Biol Med (Maywood)       Date:  2005-04

3.  C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity.

Authors:  Silvia Del Ry; Claudio Passino; Maristella Maltinti; Michele Emdin; Daniela Giannessi
Journal:  Eur J Heart Fail       Date:  2005-12       Impact factor: 15.534

4.  Cyclic GMP signaling and regulation of SERCA activity during cardiac myocyte contraction.

Authors:  Qihang Zhang; Peter M Scholz; Yiqi He; James Tse; Harvey R Weiss
Journal:  Cell Calcium       Date:  2005-03       Impact factor: 6.817

5.  Slow contractions characterize failing rat hearts.

Authors:  Janny Bøkenes; Jan Magnus Aronsen; Jon Arne Birkeland; Unni Lie Henriksen; William E Louch; Ivar Sjaastad; Ole M Sejersted
Journal:  Basic Res Cardiol       Date:  2008-03-17       Impact factor: 17.165

Review 6.  Modulation of cGMP in heart failure: a new therapeutic paradigm.

Authors:  Guido Boerrigter; Harald Lapp; John C Burnett
Journal:  Handb Exp Pharmacol       Date:  2009

Review 7.  Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications.

Authors:  Lincoln R Potter; Andrea R Yoder; Darcy R Flora; Laura K Antos; Deborah M Dickey
Journal:  Handb Exp Pharmacol       Date:  2009

8.  Role of phospholamban in cyclic GMP mediated signaling in cardiac myocytes.

Authors:  Qihang Zhang; Peter M Scholz; Anna Pilzak; Jun Su; Harvey R Weiss
Journal:  Cell Physiol Biochem       Date:  2007

9.  Cardiac transgenic and gene transfer strategies converge to support an important role for troponin I in regulating relaxation in cardiac myocytes.

Authors:  So-ichiro Yasuda; Pierre Coutu; Sakthivel Sadayappan; Jeffrey Robbins; Joseph M Metzger
Journal:  Circ Res       Date:  2007-07-05       Impact factor: 17.367

10.  SERCA inhibition limits the functional effects of cyclic GMP in both control and hypertrophic cardiac myocytes.

Authors:  Qihang Zhang; Tomer Davidov; Harvey R Weiss; Peter M Scholz
Journal:  Pharmacology       Date:  2009-03-04       Impact factor: 2.547

View more
  9 in total

1.  Elevated C-type natriuretic peptide elicits exercise preconditioning-induced cardioprotection against myocardial injury probably via the up-regulation of NPR-B.

Authors:  Jiao Lu; Shan-Shan Pan
Journal:  J Physiol Sci       Date:  2016-08-24       Impact factor: 2.781

Review 2.  Physiological and Pathophysiological Effects of C-Type Natriuretic Peptide on the Heart.

Authors:  Akihiro Yasoda
Journal:  Biology (Basel)       Date:  2022-06-14

3.  Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium.

Authors:  Lise Román Moltzau; Silja Meier; Jan Magnus Aronsen; Faraz Afzal; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Eirik Qvigstad
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-01-15       Impact factor: 3.000

4.  C-Type Natriuretic Peptide Improves Left Ventricular Functional Performance at Rest and Restores Normal Exercise Responses after Heart Failure.

Authors:  Tiankai Li; Heng-Jie Cheng; Nobuyuki Ohte; Hiroshi Hasegawa; Atsushi Morimoto; David M Herrington; William C Little; Weimin Li; Che Ping Cheng
Journal:  J Pharmacol Exp Ther       Date:  2016-03-29       Impact factor: 4.030

Review 5.  C-type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature.

Authors:  Amie J Moyes; Adrian J Hobbs
Journal:  Int J Mol Sci       Date:  2019-05-08       Impact factor: 5.923

6.  FRET-based cyclic GMP biosensors measure low cGMP concentrations in cardiomyocytes and neurons.

Authors:  Gaia Calamera; Dan Li; Andrea Hembre Ulsund; Jeong Joo Kim; Oliver C Neely; Lise Román Moltzau; Marianne Bjørnerem; David Paterson; Choel Kim; Finn Olav Levy; Kjetil Wessel Andressen
Journal:  Commun Biol       Date:  2019-10-29

Review 7.  Phosphodiesterases and Compartmentation of cAMP and cGMP Signaling in Regulation of Cardiac Contractility in Normal and Failing Hearts.

Authors:  Gaia Calamera; Lise Román Moltzau; Finn Olav Levy; Kjetil Wessel Andressen
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

8.  CNP regulates cardiac contractility and increases cGMP near both SERCA and TnI: difference from BNP visualized by targeted cGMP biosensors.

Authors:  Ornella Manfra; Gaia Calamera; Alexander Froese; Dulasi Arunthavarajah; Nicoletta C Surdo; Silja Meier; Arne Olav Melleby; Monica Aasrum; Jan Magnus Aronsen; Viacheslav O Nikolaev; Manuela Zaccolo; Lise Román Moltzau; Finn Olav Levy; Kjetil Wessel Andressen
Journal:  Cardiovasc Res       Date:  2022-05-06       Impact factor: 13.081

9.  C-type Natriuretic Peptide-induced PKA Activation Promotes Endochondral Bone Formation in Hypertrophic Chondrocytes.

Authors:  Keisho Hirota; Tsuyoshi Hirashima; Kazuki Horikawa; Akihiro Yasoda; Michiyuki Matsuda
Journal:  Endocrinology       Date:  2022-03-01       Impact factor: 4.736

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.